Expected values for cumulative productivity loss during phase II by treatment groups and marginal effects from the regression models
| ETN25+MTX (CI) | MTX (CI) | PBO (CI) | ETN+MTX−PBO (CI) | MTX−PBO (CI) | ETN+MTX−MTX (CI) | |
|---|---|---|---|---|---|---|
| Paid work productivity loss | ||||||
| Probability of paid loss=0 (part 1) | 0.60 (0.41 to 0.77) | 0.55 (0.38 to 0.70) | 0.37 (0.20 to 0.55) | 0.23 (−0.02 to 0.47)* | 0.18 (−0.05 to 0.40) | 0.05 (−0.18 to 0.29) |
| Mean loss for part 2 in hours | 134.92 (66.92 to 222.39) | 140.75 (90.91 to 192.32) | 260.95 (129.90 to 442.46) | −126.03 (−317.36 to 31.96)* | −120.20 (−308.42 to 21.99)* | −5.83 (−92.34 to 92.93) |
| Mean overall loss in hours | 53.75 (21.38 to 96.56) | 63.26 (34.04 to 99.75) | 164.48 (75.47 to 280.95) | −110.74 (−233.66 to −11.55) | −101.22 (−222.42 to −5.35) | −9.51 (−57.40 to 40.98) |
| Costs of lost paid work productivity | ||||||
| Mean costs for part 2 in € | 2151.99 (1139.64 to 3363.08) | 2463.35 (1587.26 to 3339.04) | 4146.3 (2248.05 to 6590.74) | −1994.31 (−4603.03 to 262.71)* | −1682.95 (−4344.12 to 398.51) | −311.36 (−1635.79 to 1209.43) |
| Mean overall costs in € | 844.13 (350.03 to 1495.64) | 1092.87 (582.28 to 1714.52) | 2595.80 (1283.97 to 4267.49) | −1751.67 (−3459.43 to −290.89) | −1502.93 (−3237.82 to −70.51) | −248.73 (−1026.24 to 556.60) |
| Total costs of lost productivity | ||||||
| Probability of total costs=0 (part 1) | 0.51 (0.29 to 0.7) | 0.46 (0.25 to 0.63) | 0.31 (0.13 to 0.48) | 0.20 (−0.04 to 0.45) | 0.15 (−0.09 to 0.37) | 0.06 (−0.18 to 0.31) |
| Mean total costs for part 2 in € | 2287.08 (1400.03 to 3236.83) | 3369.11 (2112.31 to 4855.12) | 4309.17 (2659.70 to 6297.79) | −2022.10 (−4136.02 to −113.61)** | −940.06 (−3266.33 to 1259.00) | −1082.03 (−2788.94 to 449.05) |
| Mean overall costs in € | 1110.63 (535.76 to 1905.42) | 1829.33 (973.74 to 3053.37) | 2972.15 (1633.7 to 4695.24) | −1861.53 (−3584.72 to −341.17) | −1142.83 (−2939.05 to 544.96) | −718.70 (−1977.25 to 355.89) |
CI, bootstrapped CI; ETN25+MTX, etanercept 25 mg plus methotrexate; PBO, placebo.
**p Value for the coefficients of ETN25+MTX and MTX compared with PBO in the models 0.01<p≤0.05; *0.05<p≤0.1; p value not applicable for overall.